Samsung Electronics Health and Medical Equipment Business and Samsung Medison participated in the 2024 Radiological Society of North America (RSNA) conference in Chicago, United States, from December 1st to 5th (local time) and unveiling an even more diverse product lineup.

To strengthen its competitiveness across medical specialties, after the launch of a new OB & GYN ultrasound diagnostic system, HERA Z20, Samsung proposed ‘pediatric integrated solution’ encompassing the entire range of its medical diagnostic devices through this RSNA.

In the ‘Ultrasound Zone,’ a dedicated probe for the pediatric cardiac diagnosis ‘TA2-9’ was unveiled for the first time at this exhibition. The TA2-9 with 42% smaller head than adult echocardiography probe aids in more accurate diagnosis for congenital heart disease or functional and structural abnormalities of heart through the oral route. Also on display was ‘L3-22’, a dedicated neonatal probe featuring a smaller head compared to an adult version offering a wide frequency range which enables pediatric body scan with a single device without the need to switch probes.

All US Food and Drug Administration (FDA) 510(k) cleared products of Samsung digital X-ray have ‘low dose’ capability making it more appropriate for diagnosis of children and adolescents where safety is particularly prioritized. Samsung’s proprietary S-Vue imaging engine reduces radiation exposure by up to 50% compared to systems without this technology.

At this exhibition, Samsung launched a new ‘floor-mounted’ digital X-ray, GF 85. The new digital X-ray, GF 85 launched by Samsung is relatively affordable compared to ceiling-mounted type and cost-effective with the ability to be installed in a small space without ceiling construction. Moreover, it provides clear image quality even with low dose and is equipped with advanced AI diagnostic assistance feature, fully inheriting all the advantages of previous digital X-ray models.

NeuroLogica Corp, a subsidiary of Samsung Electronics, includes the OmniTom Elite mobile computed tomography (CT) in its portfolio, useful for imaging pediatric patients and at point-of-care, facilitating rapid clinical decision making and reducing transport related risks. Mobile CT is already recognized for its utility, with 8 out of the top 10 U.S. pediatric hospitals (as ranked by U.S. News for 2024-2025) utilizing the technology.

NeuroLogica’s OmniTom Elite with photon counting detector (PCD) technology showcased this year’s at RSNA delivers ultra high-resolution CT imaging at the point-of-care using FDA 510(k) cleared PCD technology, surpassing conventional CT methods that rely on energy integrating detectors. By utilizing photon counting detectors to measure the energy of each individual photon, this cutting-edge technology enhances contrast differentiation and virtual monoenergetic imaging, empowering radiologists with greater confidence in diagnosing patients.

Samsung provides opportunity to gain clinical application tips of Samsung medical devices and engage in Q&A with the global experts through Lunch & Learn session. In this session, a global breast imaging expert, Dr. Nina Vincoff shared a screening program using Samsung breast ultrasound solution and the latest insights on the FDA’s mandate for breast density information provision and implementation of additional imaging examination recommendation for dense breast (effective on September 10, 2024).

Dr. Farhad Farzanegan in Kasier Permanente South Sacramento health system U.S. presented a case study on hospital workflow improvement based on the result of CT intervention procedure using Samsung mobile full-body CT, BodyTom.

In the booth, Dr. Jon Jacobson, a musculoskeletal radiology expert, conducted live scan using a premium ultrasound diagnostic device, RS85 Prestige introducing clearer image quality and more sophisticated AI diagnostic assistance feature.

The leader of the Samsung Medison AI&Informatics group, Vijay, said “I discovered a greater potential through high praises from medical professors around the world who visited the site” and “Moving forward, we aim to further enhance our AI diagnostic support features tailored to specialized medical fields, solidify our technological leadership in radiology and obstetrics, and expand our competitiveness across all medical disciplines to pioneer new markets.”

▲ NeuroLogica’s OmniTom® Elite with PCD technology has received U.S. FDA 510(k) clearance.

NeuroLogica Corp, a subsidiary of Samsung Electronics, announced its latest configuration of the mobile computed tomography (CT) OmniTom^® Elite with Photon Counting Detector (PCD) technology has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This advancement builds upon the existing PCD capabilities with groundbreaking enhancements, further solidifying OmniTom^® Elite’s position at the forefront of mobile CT imaging technology.

The newly cleared features optimized for PCD include several significant innovations:

• Ultra-High-Resolution Mode: This development promises unprecedented clarity and detail in CT imaging. The addition of an ultra-high-resolution mode now offers an impressive 0.141 mm resolution.
• Advanced Image Processing Algorithm: The OmniTom^® Elite now supports post-reconstruction features such as Virtual Non-Contrast (VNC) and bone removal, enhancing diagnostic capabilities and image quality.
• Expanded Scanning Scope: The PCD scanning capabilities now cover a full 30cm field of view, ensuring comprehensive imaging potential for a variety of clinical applications.
• Helical Scanning Capability: This new feature allows for continuous spiral scanning, providing a faster and more efficient imaging process.
• Enhanced Operating Environment: The operating environment ambient temperature has been increased, broadening the range of conditions in which the device can be used.

These enhancements mark a significant step forward from the initial PCD configuration, which was already a pioneering achievement in mobile CT technology. The original OmniTom^® Elite with PCD was the first FDA 510(k) cleared, single-source photon counting computed tomography scanner with a single detector, capable of generating spectral CT images at multiple energy levels. This enhancement marks the third 510(k) clearance for OmniTom^® Elite PCD, speaking to NeuroLogica’s commitment to continuous innovation.

“Samsung and NeuroLogica’s technological innovation has resulted in the FDA clearance of OmniTom^® Elite PCD,” said Kyu Tae Yoo, Head of Samsung Electronics’ Health & Medical Equipment Business and Samsung Medison CEO. “We will continue to develop leading technologies to improve medical staff’s convenience and diagnostic accuracy.”

Renaud Maloberti, Vice President & Head of mCT Business, NeuroLogica, commented, “Our commitment to innovation drives us to continually improve our products. With these new features, the OmniTom^® Elite PCD not only offers exquisite image quality and diagnostic capabilities but also ensures a more versatile and efficient imaging process. This is a significant advancement for point-of-care imaging, continuing our commitment to enable clinicians to make a more confident diagnosis due to the improved clinical information.”

The University of Dundee and Massachusetts General Hospital have partnered with NeuroLogica to collaborate on research aimed at pushing the boundaries of medical imaging in healthcare using OmniTom^® Elite PCD.

Existing OmniTom^® Elite customers can “UpTrade” their scanners to the OmniTom^® Elite PCD, granting them access to the latest advancements in photon counting technology.

* OmniTom^® Elite PCD is not currently US FDA 510(k) cleared for neonate or pediatric scanning and may not be commercially available in some countries. Sales and shipments are effective only after approval by the regulatory team. Please contact your local sales representative for further details. This product is a medical device; please read the user manual carefully before use.

About Neurologica
NeuroLogica Corp., the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures and markets innovative imaging technologies and is committed to delivering fast, easy, and accurate diagnostic solutions to healthcare providers. NeuroLogica is the global corporate headquarters and manufacturer of mobile computed tomography devices. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency. For more information, please visit: www.NeuroLogica.com.

NeuroLogica’s OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology.

The world of medical imaging is no longer just black & white. NeuroLogica Corp, a subsidiary of Samsung Electronics, announced today its state-of-the-art OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology. NeuroLogica delivers the first FDA 510(k) cleared, single-source photon counting computed tomography (CT) scanner with single detector. OmniTom Elite with PCD can generate spectral CT images at multiple energy levels.

Photon counting is a next-generation CT technology that sorts the different energies of X-rays after they have passed through the scan field. A single X-ray source paired with PCD generates multiple sets of CT data acquired at the same time with configurable energy thresholds without any cross talk between images. PCD provides the ability to capture CT data in multiple energy bands leading to potentially more accurate visualization and segmentation of bone, blood clots, plaque, hemorrhage and intracranial tumors. There is also potential with PCD to lower the dose requirements, and fundamentally change the use of injected contrast.

“NeuroLogica is driven by innovation. Since the advent of the world’s first multi-slice mobile CT in 2004, we have always known that point-of-care imaging can improve patient outcomes and increase the likelihood of a better quality of life after a traumatic event,” said David Webster, Chief Operating Officer of NeuroLogica. “With the introduction of PCD technology to the OmniTom Elite platform, we look to expand the diagnostic possibilities of CT at the patient’s bedside.”

The OmniTom Elite has the ability to provide versatile, real-time mobile imaging to administer point-of-care CT to critical patients without the need to transport them to a separate imaging department. The mobile unit will decrease the time it takes to diagnose and initiate treatment for these critical patients.

“Availability of photon-counting detector technology on a mobile head CT platform is a significant advance in the development of CT,” said Rajiv Gupta, PhD, MD, Neuroradiology Division Chief of Massachusetts General Hospital and Associate Professor at Harvard Medical School. “This advance heralds a new era of CT applications in stroke, trauma, ICU and intra-op settings.” MGH is collaborating with NeuroLogica and will pilot test the OmniTom Elite with PCD to monitor post-trauma and post-surgical patients.

Upgrading capabilities were top of mind when designing OmniTom Elite mobile CT scanners. In the near term, all current OmniTom users will have the opportunity to upgrade their scanners with this technology. Meanwhile, a limited number of premier research partners will aid in developing the full potential of OmniTom Elite with PCD.

Neurologica’s OmniTom Elite, and the entire mobile CT product line are manufactured in Danvers, MA, USA.

To stay informed about our PCD products, events and future developments please sign up on our website: https://www.neurologica.com/mobile-ct/PCD

About NeuroLogica

NeuroLogica Corp., the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica is the global corporate headquarters and manufacturer of mobile computed tomography devices. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency. For more information, please visit: http://www.NeuroLogica.com.

“This has been a momentous year for Samsung. We have worked to advance our solutions by leveraging high computing power and artificial intelligence (AI) technologies,” said David Legg, Vice President, Digital Radiography and Ultrasound, NeuroLogica. “We will be deploying AI features in each of our products to provide benefits to healthcare professionals and patients alike.”

Ultrasound

At the event, Samsung will showcase its new V8, which is a premium ultrasound system that provides enhanced image quality, usability and convenience for ultrasound professionals. Crystal Architecture is the core of the V8’s image clarity and penetration and is built upon the combination of innovative beamforming (CrystalBeam), sophisticated image processing (CrystalLive) and advanced S-Vue Single Crystal Transducers to produce clear, uniform and high-resolution images.

The feature-packed device includes two new AI functions, one being NerveTrack, which detects nerves and provides nerve location information in real-time to anesthesiologists and expert practitioners. The function is designed to provide users with accurate nerve detection, faster image processing and better workflow support. The second AI function is UterineAssist, which detects tissue changes and assists the user in taking measurements of the uterus. With these and other new tools, the V8 delivers a new level of versatility and value to a wide range of diagnostic medical ultrasound departments.

Samsung has also worked to advance its ultrasound solutions for women’s health. Recently, the Hera W9 and W10 received Food and Drug Administration (FDA) 510(K) clearance for its new AI functions, which gives the operator the ability to measure anatomical structures and analyze imaging, providing useful information to aid diagnosis.

New features include:

• HeartAssist: A deep learning-based function that provides classification of ultrasound images to display measurements. The feature recognizes various views and proposes caliper placements and corresponding measurements allowing users to save time with measurement proposals and increase examination efficiency by reducing keystrokes.
• ViewAssist: A deep learning-based function that classifies ultrasound images to deliver key scanning views and provides annotations. The feature recognizes a range of views, proposes corresponding anatomy annotations and initiates measurements.
• BiometryAssist: An automatic solution for biometric measurement that can be modified by the user. It enables users to measure fetal growth parameters with one click while maintaining exam consistency.

Digital Radiography

Samsung is also showcasing its premium digital mobile X-ray, the AccE GM85, which delivers unparalleled performance and gives users better diagnostic confidence while improving workflow. Recently, Samsung received FDA 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool, which can be utilized in the AccE GC85A and in other systems. The ALND is provided as an on-device computer-assisted detection (CADe) software that uses an AI algorithm to detect pulmonary nodules between 10 and 30mm in size.¹

The benefits of ALND include:

• Aids the user in the diagnostic process by indicating the location of suspected lung nodules on chest X-ray images (posteroanterior chest radiographs).
• Offers the option (Autorun) to automatically perform nodule detection immediately after chest X-ray imaging in addition to PACS transmission options to suit the hospital environment, both of which simplify the user’s workflow.
• The ALND has been clinically verified by multiple university hospitals and has been approved with a sensitivity of 80% or more.² As part of Samsung’s commitment to advancing diagnostic radiology using AI, Samsung will expand the uses of the chest CADe solution and continue improving diagnostic accuracy and workflow.

Computed Tomography

Also featured at RSNA is the OmniTom^® Elite – a mobile computed tomography (CT) scanner that delivers high-quality non-contrast CT, CT angiography and CT perfusion scans at point-of-care. The OmniTom Elite CT boasts a small footprint and high-resolution image quality. The advancements of the scanner help to optimize diagnostic confidence, speed and workflow across departments, such as neurosurgery, pediatric imaging, critical care, diagnostic radiology and more.

Earlier this year, NeuroLogica announced that the OmniTom Elite with Photon Counting Detector (PCD) technology will be piloted by Massachusetts General Hospital, bringing CT imaging to the patient’s point-of-care. Pending FDA 510(k) clearance, the hospital is testing the OmniTom Elite with PCD to monitor post-trauma and post-surgical patients.

The OmniTom Elite’s ability to provide versatile, real-time mobile imaging enables healthcare providers to administer point-of-care CT to critical patients without the need to transport them to a separate department. The mobile unit will decrease the time it takes to diagnose and initiate treatment for patients in the ICU. During the pilot stage for the OmniTom Elite with PCD, Massachusetts General Hospital will guide best practices and evaluate use cases for the novel system.

Visit Samsung at Booth #6952.

Samsung will showcase its premium diagnostic imaging solutions in ultrasound, digital radiography and mobile computed tomography at the Radiological Society of North America (RSNA) 2021 Annual Meeting.

About Samsung Medison Co., Ltd.

Samsung Medison is a global leading medical device company, founded in 1985. With a mission to bring health and well-being of people’s lives, the company manufactures diagnostic ultrasound systems around the world across various medical fields. In 2011, Samsung Medison became an affiliate company of Samsung Electronics, integrating world’s best IT, image processing, semiconductor and communication technologies into medical devices.

About NeuroLogica Corp.

NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of mobile computed tomography, is also the US headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. For more information, please visit http://www.NeuroLogica.com.

* Content has been updated as of February 10, 2023 to more accurately reflect product information.

¹ ALND cannot be used on patients who have lung lesions other than abnormal nodules.

² Y. Sim et al, Deep Convolutional Neural Network-based Software Improves Radiologist Detection of Malignant Lung Nodules on Chest Radiographs. Radiology, 2020

Samsung Electronics will showcase its premium diagnostic imaging solutions in ultrasound, digital radiography and mobile computed tomography at the Radiological Society of North America (RSNA) 2020 Annual Meeting from November 29 to December 5.

“This year has been a pivotal year for Samsung in moving forwards new solutions across a variety of areas. We are looking forward to putting on display our advancements within ultrasound, digital radiography and mobile CT modalities,” stated Yongkwan Kim, Head of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “Our innovative solutions demonstrate Samsung’s commitment to leveraging our innovation engine to better address the needs of healthcare providers and their patients.”

Ultrasound

Samsung will showcase the RS85 Prestige, which is designed to deliver outstanding scanning performance with consistent image clarity, depth of penetration and sensitivity to perfusion of blood flow to enhance abdominal and breast examination functionality. Above all, the RS85 Prestige delivers real-time images to clinicians, which is essential in ultrasound imaging.

New features:

• EzHRI assists in diagnosing fatty livers by showing the degree of the fatty liver after analyzing the ultrasound images and comparing the brightness level of the automatically selected location of hepatic parenchyma and renal cortex.
• TAI (Tissue Attenuation Imaging), TSI (Tissue Scatter distribution Imaging) provide quantitative tissue attenuation measurement and tissue scatter distribution measurement to assess steatotic liver changes.
• LA2-14A is an S-Vue Transducerwith single crystal technology, providing clear distinction in images of anatomical structures based on high SNR and deep penetration. As a single crystal transducer added to the high-resolution imaging technology, Crystal Architecture, useful images are provided for diagnosing thyroid and breast tumors as well as MSK tendon-related disorders.

Additional features deliver simplified workflow and accurate diagnoses:

• S-Detect simplifies breast examination processes by providing analysis of the selected lesion and standard reporting based on BI-RADS ATLAS*(Breast Imaging-Reporting and Data System, Atlas).
• S-Shearwave Imaging allows for non-invasive assessment of the stiffness of tissue/lesions in applications such as breast, liver, MSK and prostate, aided by color-coded elastogram, quantitative measurements, dual or single display options, and user-selectable ROI functions. It aids in the diagnosis of hepatocirrhosis and tumors.

Digital Radiography

Samsung is showcasing its premium digital mobile x-ray, the AccE GM85, which delivers unparalleled performance by improving diagnostic confidence and workflow. The AccE GM85, powered by a lithium-ion battery, in particular has demonstrated unprecedented performance during the recent pandemic. The AccE GM85 is suited to general imaging needs, and its practicality during the COVID-19 pandemic is highlighted through its unique feature set.

• Fast charging and long-lasting battery allows full charge within four hours, and the power to keep going all day without need for additional charging. With Li-ion battery technology, it offers enhanced stability in wider temperature ranges and its lead-free composition is more friendly for the environment.
• SimGrid streamlines workflow and reduces the total exam time by 28% by omitting grid installation and removal from the conventional workflow.
• S-Vue provides better image quality and significantly reduces radiation dosage during exams. The dosage can be reduced by up to 45% for pediatric abdomen, 15.5% for pediatric chest, and 27% for pediatric skull exams with the new S-Vue engine.¹

Samsung will be introducing two new enhanced software options for its line of DR equipment, including:

• Value Up Package 2021, a suite of workflow enhancement and diagnostic tools for Samsung DR systems including an AI algorithm that automatically provides a heads-up view of chest AP/PA; enhanced S-Align function with information of tube and detector angle to DICOM; and many other tools to deliver improved clinical care.
• Mirror View, real-time wireless screen mirroring to a Smart TV or Miracast-enabled display for use within an ER/Trauma or operating room environment.

Computed Tomography

Featured at RSNA are BodyTom^® Elite and OmniTom^® – mobile whole-body and head CTs. These mobile CTs can be used at the point of care, whenever imaging is needed to determine the ideal treatment strategy for a patient – without restrictions of physical space and power. Samsung’s NeuroLogica mobile CT devices are used by numerous leading institutions in intensive care units, emergency rooms, orthopedic and neurosurgery rooms, brachytherapy suites and ambulances.

In addition, Samsung will be presenting a Photon Counting Detector (PCD)² – cutting-edge technology that measures photons emitted by X-rays. The PCD, currently under development, has the potential to allow for dose optimization, allowing the user to reduce exposure while maintaining image quality, or increase the image quality by keeping dose equivalence compared to currently used CT detectors. The PCD is expected to deliver increased data mining capabilities from multiple-energy detection and contribute to the improved utility and efficacy of AI applications. Expanding from this, Samsung is closely collaborating with a major university hospital in the United States.

Samsung will host three Industry Sessions during RSNA:

• Featured Demonstration about advanced imaging technologies with RS85 Prestige will be held on December 3, from 5:00 p.m. CT – 5:30 p.m. CT.
• AI Theater Presentation: Application of On-Device AI in Healthcare, in collaboration with Intel,³ will discuss On-Device AI solutions that provide real-time feedback on ultrasound images and protect patients’ personal information. As a part of this collaboration, Samsung will host an Industry Session to address the differences between Cloud AI and On-Device AI, and the significance in ultrasound, available on demand throughout the duration of RSNA.
• Innovation Theater will highlight the performance of Auto Lung Nodule Detection (ALND)⁴ imaging application on chest radiographs of COVID-19 patients, available on demand throughout the duration of RSNA.

About Samsung Medison

Samsung Medison is a global leading medical device company, founded in 1985. With a mission to bring health and well-being of people’s lives, the company manufactures diagnostic ultrasound systems around the world across various medical fields. In 2011, Samsung Medison became an affiliate company of Samsung Electronics, integrating world’s best IT, image processing, semiconductor and communication technologies into medical devices.

About NeuroLogica

NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of mobile computed tomography, is also the US headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. For more information, please visit http://www.NeuroLogica.com.

¹ The S-Vue outcome is based on limited phantom and clinical study results. Only routine PA chest radiography and abdominal radiography for average adults and pediatric abdominal, chest, skull radiography were studied, excluding pediatric patients under 1 month old. (FDA cleared – K172229, K182183) In practice, the values of dose reduction may vary accordingly.

² Product is under development and not available for sale in USA or any region of the world.

³ Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.

⁴ ALND is not available for commercial sale in the USA.

Visitors awaiting Samsung Electronics’ CT unveiling at the RSNA’s 101st annual meeting on November 28.

Samsung Electronics is strengthening its commitment to delivering fast, reliable, smart and innovative diagnostic solutions for healthcare providers by debuting the newest additions to its portfolio, on display at the Radiological Society of North America (RSNA) Annual Meeting at McCormick Place in Chicago. This week at booth #7313 (North Building, Hall B), product specialists will be on hand demonstrating Samsung’s range of solutions in Computed Tomography (CT), Ultrasound and Digital Radiography (DR) systems, which are all designed to enrich the quality of care and workflow, and enhance the patient experience.

“Through our innovative designs and advanced technologies, we remain committed to delivering new solutions, like the NExCT 7 and the RS80A with Prestige, that unlock workflow efficiencies for medical professionals as well as improve patients’ lives,” said Soo-In Cho, President and Head of the Health & Medical Equipment Business at Samsung Electronics Co., Ltd. “By leveraging the combination of Samsung imaging technology and user-inspired design, we will continue to deliver on our promise of fast, easy and accurate diagnostic solutions for our customers in the healthcare community.”

Wayne Spittle, Executive Vice President of Samsung Medison, introducing the NExCT 7, Samsung’s first CT scanner.

Computed Tomography (CT) Segment

Samsung’s CT imaging solutions are used throughout the world in intensive care units, neurosurgical operating rooms, emergency departments, stroke centers and other key clinical areas. Debuting at RSNA is:

• NExCT 7 – the first premium CT scanner from Samsung features high resolution designed to improve diagnostic confidence in advanced and routine exams reducing the radiation dose as low as reasonably achievable and ensuring a fast and efficient workflow. Some features of the NExCT7 are FDA 510(k) pending.

• Portable CT – Samsung will be showcasing the latest in software and hardware enhancements across its portable CT product line. These upgrades improve user satisfaction and streamline workflow, and both systems are now compliant with the Smart Dose (XR-29) radiation dose reporting standard.

The BodyTom and CereTom portable systems continue to prove their versatility as they are increasingly adopted and utilized in a wide range of market applications such as mobile stroke units, brachytherapy suites, proton therapy centers, deep brain stimulation and even veterinarian hospitals.

Ultrasound Segment

Samsung continues to enhance the user experience with its cutting-edge diagnostic ultrasound devices around the world and across various medical fields. On display at RSNA are:

• RS80A with Prestige – now available in the U.S. market, this system features advanced technical capabilities built on the successes of Samsung technologies. Product features include:

• S-Fusion to enable simultaneous localization of lesions with a real-time ultrasound image supported by other modalities’ 3D data sets. Fusion speed and accuracy are the strengths of S-Fusion.
• S-Shearwave to detect the velocity of the shearwave transmitted through the targeted lesion and display the numerical measurement of stiffness.
• E-Breast*: this is the function for breast lesion exam, which calculates the strain between the area of the suspected lesion (ROI) and normal breast fat and displays the results.
• E-Thyroid*: This function assists with the diagnosis of thyroid lesions. The ROI is used to show the contrast of an elastogram.*The strain ratio value is a relative value regarding quantification, not an absolute value.

• HS70A – designed for hospital and private care. This system has a flexible architecture to meet the clinical needs of varied users. The HS70A offers a complete Radiology and Cardiovascular solution, including technologies migrated from the premium radiology RS80A platform. Features include S-Detect, which uses Breast Imaging-Reporting, and Data System (BI-RADS®) scores for analysis and classification of suspicious lesions.

Digital Radiography (DR) Segment

Samsung’s DR systems combine advanced imaging technology, award-winning design and user-friendly automated workflows to meet the demands of 21st century radiology departments. Products on display at RSNA include:

• GC85A – a DR system offering streamlined workflow, diagnostic confidence and improved total cost of ownership. The GC85A features imaging engine S-Vue, ensuring consistency with high quality, convenient setting of contrast and improved sharpness and clarity, S-Share to support unique clinical needs and continuous care with increased connectivity, and Smart Control for one-touch precise positioning.
• GM60A – a mobile Digital Radiography system that delivers high-quality imaging directly to the patient’s bedside. Advanced mobility allows use in the patient room, emergency room, operating room and the intensive care unit, and has advanced features, including S-Detector and S-Vue imaging technologies to deliver accurate diagnoses while ensuring reliable operation with enhanced usability. Additionally, the telescopic column ensures fast navigation by securing a clear view for users.

For more information about Samsung’s showcase at RSNA, please visit http://www.samsung.com/rsna2015.

To learn more about Samsung’s healthcare work, please visit samsung.com/global/business/healthcare/.

About NeuroLogica

NeuroLogica, a healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of computed tomography, is also the U.S. headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. Samsung is committed to being leaders in the field of healthcare imaging. For more information, please visit www.SamsungNeuroLogica.com.